PBM lobby goes on the offensive

The Hill· June 29, 2026

The Pharmacy Benefit Manager (PBM) lobby is reportedly initiating a proactive advocacy campaign to counter increasing legislative and regulatory scrutiny. This strategic move comes as policymakers focus on the impact of PBM practices on drug pricing and the broader healthcare supply chain. For the pharmaceutical industry, these lobbying efforts are critical to monitor as they may influence future rebate structures, transparency requirements, and market access dynamics.

Read the full story at The Hill

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to The Hill.

More in Pharmaceutical

FDA Chooses 7 Companies for PreCheck Pilot

The U.S. Food and Drug Administration has announced the selection of seven companies to participate in its new PreCheck pilot program. This initiative aims to explore more efficient regulatory pathways and oversight mechanisms for the pharmaceutical industry. The program's outcomes could influence future compliance standards and the speed of regulatory approvals for participating manufacturers. By collaborating with these selected firms, the FDA intends to modernize its approach to industry oversight and supply chain integrity.

June 30, 2026

GAO Report Finds Federal Research Fuels Pharmaceutical Profits with Minimal Taxpayer Return

A new Government Accountability Office (GAO) report released in June 2026 investigates how federal research funding translates into private pharmaceutical profits. The report highlights the role of agencies like the National Institutes of Health (NIH) in bearing the financial risk of early-stage discovery before private companies license the findings for commercial development. This examination is critical for the pharmaceutical sector as it addresses the growing tension between public investment in innovation and the high cost of resulting medications for U.S. patients.

June 30, 2026

Seven Companies Selected for FDA Pilot to Strengthen US Drug Supply Chain

The U.S. Food and Drug Administration has selected seven companies to participate in a new pilot program focused on strengthening the domestic pharmaceutical supply chain. This initiative aims to enhance the security and resilience of drug distribution networks to prevent critical medicine shortages. For the pharmaceutical sector, this program represents a significant effort to modernize logistics and ensure the continuous availability of essential treatments for patients. By collaborating with industry partners, the FDA seeks to identify best practices that can be scaled to protect the integrity of the entire U.S. drug market.

June 30, 2026

Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme

Eli Lilly and Regeneron have been identified as early participants in the FDA’s new fast-track facility scheme. This program is designed to expedite the regulatory review and approval process for pharmaceutical manufacturing sites. By streamlining these inspections, the initiative aims to facilitate faster market entry for critical medications and improve supply chain efficiency. The involvement of these major incumbents underscores the pharmaceutical industry's move toward modernized regulatory frameworks for production infrastructure.

June 30, 2026